Cellular Anti-Gp120 Cytolytic Reactivities in Hiv-1 Seropositive Individuals

Weinhold, K J; Matthews, T J; Ahearne, PaulM.; Langlois, Alphonse J.; Lyerly, H. Kim; Tyler, DouglasS.; Stine, KimoC.; Durack, D T; Bolognesi, D. P.

doi:10.1016/s0140-6736(88)91713-8

Cited by 115 publications

(38 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correlation analyses partly supported that CTL activity was related to percentage of T cells, as CTL activity was correlated with the percentage of CD3 þ T cells. Our results differ from those of other studies that used higher doses of recombinant IL-2 or its polyethylene glycol derivative (PEG IL-2) administered s.c. Schwartz et al [22] NK-and LAK-cell activities are depressed even during the asymptomatic period of HIV infection [2,22,29,30]. IL-2 therapy showed improved NK and LAK activity accompanied with an increase in the number and percentage of NK cells during the first 8 weeks of therapy.…”

Section: Immunological Effects Of Il-2 Therapy In Hiv Infectionmentioning

confidence: 99%

Effects of Subcutaneous Interleukin‐2 Therapy on Phenotype and Function of Peripheral Blood Mononuclear Cells in Human Immunodeficiency Virus Infected Patients

et al. 2000

View full text Add to dashboard Cite

In the context of clinical therapy with recombinant human interleukin‐2 (IL‐2), we monitored immunological alteration in 10 human immunodeficiency virus type‐1 (HIV‐1)‐infected individuals, on stable antiretroviral therapy, who had a CD4+ cell count between 200 and 500 cells/mm3. Subcutaneous IL‐2 was prescribed thrice weekly (at a dose of 3 × 106 IU) for 24 weeks and the patients were followed‐up for 32 weeks. IL‐2 treatment induced an increase in the CD4+ percentage (P < 0.001) and CD4+ cell count (P < 0.009). Furthermore, natural killer (NK) cell activity was increased (P < 0.001) at week 8 of treatment, whereas lymphokine‐activated killer (LAK) cell activity showed a transient, nonsignificant increase at week 8 and was reduced (P < 0.001) at 32 weeks. However, the cytotoxic T‐lymphocyte (CTL) activity decreased against HIV antigens, and the proliferative response to Candida, IL‐2 and phytohaemagglutinin (PHA) declined during the first 8 weeks (P < 0.05) and returned to baseline levels after 32 weeks. The HIV RNA level did not change during IL‐2 therapy; however, after 8 weeks of follow‐up a significant increase (P < 0.001) in viral load was observed. In conclusion, continuous IL‐2 treatment to HIV‐infected individuals enhanced the CD4 count, but the in vitro lymphocyte function was impaired and an increase in viral replication occurred after treatment.

show abstract

Section: Immunological Effects Of Il-2 Therapy In Hiv Infectionmentioning

confidence: 99%

Effects of Subcutaneous Interleukin‐2 Therapy on Phenotype and Function of Peripheral Blood Mononuclear Cells in Human Immunodeficiency Virus Infected Patients

et al. 2000

View full text Add to dashboard Cite

show abstract

“…These uninfected cells are then recognized as virus-infected cells by NK effector cells or CTL (636,1099,1260,1261) and subsequently destroyed, even though they are not infected by the virus. This hypothesis requires the detection of circulating gpl20 in the blood of individuals or on uninfected cells.…”

Section: Bystander Effectmentioning

confidence: 99%

Pathogenesis of Human Immunodeficiency Virus Infection

Levy¹

1989

Annals of the New York Academy of Sciences

222

290

View full text Add to dashboard Cite

“…Numerous studies have demonstrated the presence of specific, potentially protective activities ofthe immune system, such as neutralizing antibodies (12)(13)(14)(15)(16)(17)(18), cell-mediated cytotoxicity (19)(20)(21)(22)(23), and antibody-dependent cellular cytotoxicity ( 18,(24)(25)(26)(27)(28)(29), in individuals with HIV infection, but no study to date has convincingly demonstrated which specific immune mechanisms, if any, will protect against HIV infection or HIVinduced immunosuppression in humans. Moreover, the presence of a hypervariable region in the principal neutralizing domain as well as in other regions of the HIV outer envelope protein, gp120, has raised concerns that HIV will be able to evade the effects of neutralizing antibodies through changes in these regions ( 13-17, 30, 31 ).…”

Section: Introductionmentioning

confidence: 99%

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Kovacs

Vasudevachari²,

Easter³

et al. 1993

J. Clin. Invest.

View full text Add to dashboard Cite

Development of an effective vaccine for prevention of infection with HIV would provide an important mechanism for controlling the AIDS epidemic. In the current study, the first clinical trial of a candidate HIV-1 vaccine initiated in the United States, the safety and immunogenicity of escalating doses (10-1,280 Aig) of recombinant gp160 (rgpl6O), were evaluated in 138 HIV-negative volunteers. Maximal antibody responses, as evaluated by ELISA, were seen after immunization with three doses of 1,280 ;&g rgpl6O. Responses to some specific epitopes of HIV gp160, including the second conserved domain and the CD4 binding site, were seen more frequently than after natural infection. Neutralizing antibodies to the homologous HIV strain, but not heterologous strains, were induced by this regimen. Blastogenic responses to rgpl60 were seen in most volunteers receiving at least two doses of 2 20 Mg. These envelopespecific T cell responses were also seen against heterologous strains of HIV. No major adverse reactions were seen after immunization. Thus, rgpl60 is a safe and immunogenic candidate HIV vaccine; further studies are needed to determine if it will provide any clinical benefit in preventing HIV infection. (J. Clin. Invest. 1993. 92:919-928.)

show abstract

Cellular Anti-Gp120 Cytolytic Reactivities in Hiv-1 Seropositive Individuals

Cited by 115 publications

References 20 publications

Effects of Subcutaneous Interleukin‐2 Therapy on Phenotype and Function of Peripheral Blood Mononuclear Cells in Human Immunodeficiency Virus Infected Patients

Effects of Subcutaneous Interleukin‐2 Therapy on Phenotype and Function of Peripheral Blood Mononuclear Cells in Human Immunodeficiency Virus Infected Patients

Pathogenesis of Human Immunodeficiency Virus Infection

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Contact Info

Product

Resources

About